Summer 2026

Business Data Analytics Intern

Market Analysis

Posted on 2/6/2026

Deadline 2/6/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Franklin, MA, USA

In Person

Category
Data & Analytics (1)
Required Skills
Python
R
Forecasting
SQL
Excel/Numbers/Sheets
Requirements
  • Current MBA student with a concentration in Business Analytics, Data Science, Marketing Analytics or a related field.
  • Strong analytical and quantitative skills, with experience in data modeling, forecasting, or market sizing.
  • Proficiency with analytical tools such as Excel, SQL, Python, R, or similar platforms.
  • Ability to translate complex data sets into clear, actionable business insights.
  • Strong communication and presentation skills, with comfort engaging cross-functional teams.
  • Interest in life sciences, diagnostics, analytical instrumentation, or healthcare markets.
  • Self-starter with strong attention to detail and the ability to work independently in a
Responsibilities
  • Develop a standardized market-sizing model using laboratory‑level data to estimate customer potential across Waters’ clinical LC-MS/MS solutions and BD’s diagnostic solutions.
  • Integrate and analyze diverse datasets, including lab testing volumes, installed base information, workflow characteristics, and market benchmarks.
  • Build methodologies to identify cross‑selling opportunities between Waters’ LC-MS/MS platforms and BD’s diagnostic instruments, assays, and automation solutions.
  • Partner with commercial, marketing, commercial excellence, and product management teams at both companies to ensure the model aligns with strategic priorities and real‑world customer workflows.
  • Create dashboards, visualizations, and executive‑ready presentations that clearly communicate insights and recommendations. Document analytical assumptions, data sources, and model logic to support transparency, scalability, and future enhancements.
  • Prepare and deliver executive‑ready summaries and documentation, ensuring clear handoff of datasets, assumptions, dashboards, and recommendations for continued use beyond the internship.
Desired Qualifications
  • Experience with data visualization tools (e.g., Power BI, Tableau) is preferred.

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • BioResolve and GTxResolve columns strengthen Waters’ biopharma consumables franchise.[1]
  • omniDAWN expands large-molecule characterization into aggregates, viral vectors, and LNPs.[1]
  • Integration of instruments with software supports recurring informatics and service revenue.[1][4]

What critics are saying

  • Agilent, Thermo Fisher, and Bruker can match features and pressure margins.
  • Consumables demand depends on continued GLP-1 and LNP biopharma growth.
  • China exposure remains a vulnerability if procurement or localization pressures intensify.

What makes Waters Corporation unique

  • Embedded in regulated, high-volume pharma QA/QC, clinical, and diagnostics workflows.[2]
  • Offers analytical systems, software, and services across chromatography and mass spectrometry.[4]
  • Focuses on scientists needing precise, reproducible results in critical applications.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Waters Corporation who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.

INACTIVE